NO20040484L - Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT). - Google Patents

Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).

Info

Publication number
NO20040484L
NO20040484L NO20040484A NO20040484A NO20040484L NO 20040484 L NO20040484 L NO 20040484L NO 20040484 A NO20040484 A NO 20040484A NO 20040484 A NO20040484 A NO 20040484A NO 20040484 L NO20040484 L NO 20040484L
Authority
NO
Norway
Prior art keywords
water
mct
excipient
aqueous dispersion
chain length
Prior art date
Application number
NO20040484A
Other languages
English (en)
Norwegian (no)
Inventor
Pia Margaretha Cecilia Hedberg
Urban Tommy Skantze
Lars Christian Von Corswant
Anna Elisabeth Zackrisson
Per Lennart Lindfors
Ulf Olsson
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0119081A external-priority patent/GB0119081D0/en
Priority claimed from GB0212463A external-priority patent/GB0212463D0/en
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20040484L publication Critical patent/NO20040484L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Dental Preparations (AREA)
NO20040484A 2001-08-06 2004-02-03 Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT). NO20040484L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119081A GB0119081D0 (en) 2001-08-06 2001-08-06 Process
GB0212463A GB0212463D0 (en) 2002-05-30 2002-05-30 Process
PCT/GB2002/003583 WO2003013472A1 (en) 2001-08-06 2002-08-01 Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (mct)

Publications (1)

Publication Number Publication Date
NO20040484L true NO20040484L (no) 2004-03-31

Family

ID=26246405

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040484A NO20040484L (no) 2001-08-06 2004-02-03 Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).

Country Status (19)

Country Link
US (1) US20050009908A1 (https=)
EP (1) EP1416917B1 (https=)
JP (1) JP4714412B2 (https=)
KR (1) KR100914113B1 (https=)
CN (1) CN1254233C (https=)
AT (1) ATE365537T1 (https=)
AU (1) AU2002317409B2 (https=)
BR (1) BR0211705A (https=)
CA (1) CA2456180C (https=)
CY (1) CY1107059T1 (https=)
DE (1) DE60220923T2 (https=)
DK (1) DK1416917T3 (https=)
ES (1) ES2287293T3 (https=)
IL (2) IL160103A0 (https=)
MX (1) MXPA04001071A (https=)
NO (1) NO20040484L (https=)
NZ (1) NZ530916A (https=)
PT (1) PT1416917E (https=)
WO (1) WO2003013472A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CA2527033A1 (en) * 2003-06-18 2004-12-23 Astrazeneca Ab 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
WO2006069098A1 (en) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Nanoparticulate bicalutamide formulations
AU2006280511A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process
JP5571380B2 (ja) * 2006-07-24 2014-08-13 ルミナス バイオサイエンシズ，インコーポレイテッド オストワルド熟成を減少させた水不溶性の医薬品物質の固体ナノ粒子処方物
US20100260691A1 (en) * 2006-07-31 2010-10-14 Narayanan Kolazi S Aqueous compositions containing a hydrophobic material
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100068287A1 (en) * 2007-02-09 2010-03-18 Astrazeneca Ab Process for Preparation of a Stable Dispersion of Solid Amorphous Submicron Particles in an Aqueous Medium
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
CA2715348A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
BRPI1004808B1 (pt) * 2010-10-27 2020-09-29 Embrapa - Empresa Brasileira De Pesquisa Agropecuária Composições baseadas em nanopartículas de própolis, processos de obtenção e uso
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
PT106738B (pt) 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
JP2016507542A (ja) * 2013-02-08 2016-03-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 反応型噴霧乾燥による無機／有機複合材料の製造
WO2019055525A1 (en) * 2017-09-12 2019-03-21 Raj Selvaraj FORMULATION OF SOLID NANOPARTICLES OF WATER-INSOLUBLE PHARMACEUTICAL SUBSTANCES WITH REDUCED OSTWALD CURING
MX2024005292A (es) 2021-11-05 2024-05-17 Cinclus Pharma Holding Ab Publ Polimorfos de la sal de clorhidrato de glurato de linaprazan.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224131B2 (de) * 1972-05-17 1974-06-27 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Gewinnung des Enzyms Cholesterinoxydase, welches Cholesterin mit O tief 2 zu Cholestenon und H tief 2 O tief 2 oxydiert
US4348385A (en) * 1980-11-17 1982-09-07 Mobay Chemical Corporation Flowable pesticides
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4799962A (en) * 1987-12-24 1989-01-24 Aqualon Company Water-soluble polymer dispersion
US5145648A (en) * 1988-06-28 1992-09-08 Matsushita Electric Industrial Co., Ltd. Exhaust smoke purifier apparatus
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
ES2078447T3 (es) * 1990-06-15 1995-12-16 Merck & Co Inc Un procedimiento de cristalizacion para mejorar la estructura y el tamaño de los cristales.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU671965B2 (en) * 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Pharmaceutically Applicable Nanosol and Process for Preparing The Same
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468604A (en) * 1992-11-18 1995-11-21 Eastman Kodak Company Photographic dispersion
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
SE9303281D0 (sv) * 1993-10-07 1993-10-07 Astra Ab New formulation
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
AU4807197A (en) * 1996-10-03 1998-04-24 Paul Bunn Hydrophilic microparticles and methods to prepare same
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations

Also Published As

Publication number Publication date
EP1416917B1 (en) 2007-06-27
KR100914113B1 (ko) 2009-08-27
JP2005500362A (ja) 2005-01-06
IL160103A (en) 2008-11-26
JP4714412B2 (ja) 2011-06-29
CA2456180C (en) 2011-10-11
PT1416917E (pt) 2007-08-16
MXPA04001071A (es) 2004-05-20
CY1107059T1 (el) 2012-10-24
BR0211705A (pt) 2004-09-28
IL160103A0 (en) 2004-06-20
ATE365537T1 (de) 2007-07-15
ES2287293T3 (es) 2007-12-16
CN1564677A (zh) 2005-01-12
DK1416917T3 (da) 2007-09-17
CA2456180A1 (en) 2003-02-20
HK1064048A1 (en) 2005-01-21
NZ530916A (en) 2005-07-29
EP1416917A1 (en) 2004-05-12
WO2003013472A1 (en) 2003-02-20
CN1254233C (zh) 2006-05-03
KR20040025739A (ko) 2004-03-25
DE60220923D1 (de) 2007-08-09
AU2002317409B2 (en) 2007-06-21
DE60220923T2 (de) 2008-03-06
US20050009908A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20040484L (no) Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).
EP1829530A3 (en) Stabilization of active agents by formulation into nanoparticulate form
WO2002096457A3 (en) Stable liquid formulations of antibodies
ATE448833T1 (de) Haarbehandlungsmittel
CY1111817T1 (el) Απομακρυνση του διαλυτη με μια διαδικασια προσθιας οσμωσης
ATE332756T1 (de) Selbstreinigende sprühdüse
WO2005023923A3 (en) Methods of processing nanocrystals, and compositions, devices and systems including same
ATE399566T1 (de) Stabile dispersion fester teilchen mit einer wasserunlöslichen pyrazin-verbindung
AU2002311798A1 (en) Granulation method and device using focused acoustic energy
AU2002212412A1 (en) Method for making very fine particles consisting of a principle inserted in a host molecule
HUP0102465A3 (en) Process for the production of an aqueous monoester peroxycarboxylic acid solution, the solution obtainable by this process, and its use as disinfectant
GB2396556B (en) Particles comprising a biopolymer which is degradable under the effect of an electromagnetic wave as emitted by a solar radiation
WO2004071466A3 (en) Manufacturing process for liposomal preparations
DE502006005846D1 (de) Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
WO2003013435A3 (en) N-acetyl-d-glucosamine and process for producing n-acetyl-d-glucosamine
MXPA02011741A (es) Eteres de celulosa con disolucion retardada y un procedimiento para su fabricacion.
AU2003277732A1 (en) Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
WO2001062088A3 (en) Safening high concentrations of phytocatalysts
ATE449643T1 (de) Verfahren zur stabilisierung von peroxycarbonsäuren in tensidhaltigen dispersionen
WO2002000769A3 (en) Method for the dispersal of polyacrylamides
AU6924501A (en) Method for isolating and purifying a protein and resulting protein
WO2001093910A3 (de) Verfahren zur erhöhung des antioxidativen potentials selehaltigen wässrigen losungen
DE602004029561D1 (de) Mikrowellenplasmaverarbeitungsverfahren
ITSA20030013A1 (it) Manufatti microporosi e nanoporosi a base di
ATE440594T1 (de) Herstellung von kolloidale teilchen enthaltenden pulvern

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application